Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Khiron Life Sciences Corp V.KHRN.H

Alternate Symbol(s):  KHRNF | KHRWF | V.KHRN.WT.H

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by Benedictuson May 29, 2020 1:08am
240 Views
Post# 31086027

RE: Horrible First Quarter 2020 Results

RE: Horrible First Quarter 2020 Results Cash burn is as expected. 2020 is all about proving out their medical model with the clinics and distribution networks they've methodically built out. They will need to show incredible patient growth leading up to treating at least 40 to 50k ongoing patients across all regions (I.e. Columbia, Peru, UK, Brazil) by eoy. This will enable them to gain market credibility and do a raise late this year or early next year so they can continue their strategy. That's what the market is looking to hear about. The market will reward or punish the sp based solely on how quickly they're adding patients/clients to the network. All imo. 
<< Previous
Bullboard Posts
Next >>